Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: AstraZeneca PLC

Market Cap 280B 243B 224B 210B 392B 26,787B 400B 2,669B 1,034B 12,912B 1,050B 1,028B 44,896B P/E Ratio 2026 *
22.7x
P/E Ratio 2027 * 19.8x
Enterprise Value 299B 260B 239B 224B 419B 28,663B 428B 2,856B 1,106B 13,817B 1,124B 1,100B 48,040B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.35x
Free-Float
96.63%
Yield 2026 *
1.85%
Yield 2027 * 1.95%
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 280B
+2.32%+2.69%+42.91%+159.50% 1,013B
+0.33%+5.03%+54.35%+49.87% 574B
+0.60%+0.26%+17.77%+63.75% 397B
-0.37%+4.97%+21.24%+15.95% 324B
+2.10%+4.92%+25.30%+33.80% 273B
+5.05%+1.37%+20.05%+61.17% 182B
-0.19%-0.46%-45.32%-48.35% 194B
+4.64%-2.82%+14.86%+61.24% 151B
+2.79%+1.79%+6.83%-34.46% 146B
Average +0.86%+2.55%+17.55%+40.27% 361.64B
Weighted average by Cap. +0.80%+4.04%+28.77%+72.50%

Financials

2026 *2027 *
Net sales 63.32B 54.95B 50.65B 47.46B 88.68B 6,063B 90.53B 604B 234B 2,923B 238B 233B 10,162B 67.16B 58.28B 53.72B 50.34B 94.05B 6,430B 96.01B 641B 248B 3,100B 252B 247B 10,777B
Net income 12.43B 10.79B 9.94B 9.32B 17.41B 1,190B 17.77B 119B 45.92B 574B 46.66B 45.65B 1,995B 14.09B 12.22B 11.27B 10.56B 19.73B 1,349B 20.14B 134B 52.04B 650B 52.88B 51.74B 2,260B
Net Debt 19.6B 17.01B 15.68B 14.69B 27.44B 1,876B 28.01B 187B 72.4B 904B 73.56B 71.98B 3,145B 12.67B 10.99B 10.13B 9.49B 17.74B 1,213B 18.11B 121B 46.8B 585B 47.55B 46.53B 2,033B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
180.37USD
Average target price
220.95USD
Spread / Average Target
+22.50%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!